Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Immunol. 2013 Apr;25(2):206-13. doi: 10.1016/j.coi.2012.11.003. Epub 2012 Dec 6.

Leveraging fluorinated glucosamine action to boost antitumor immunity.

Author information

  • Department of Dermatology, Brigham and Women's Hospital, Boston, MA 02115, United States. cdimitroff@rics.bwh.harvard.edu

Abstract

N-acetyllactosaminyl glycans are key regulators of the vitality and effector function of antitumor T cells. When galectin-1 (Gal-1) binds N-acetyllactosamines on select membrane glycoproteins on antitumor T cells, these cells either undergo apoptosis or become immunoregulatory. Methods designed to antagonize expression or function of these N-acetyllactosamines on N-glycans and O-glycans have thus intensified. Since tumors can produce an abundance of Gal-1, Gal-1 is considered a critical factor for protecting tumor cells from T cell-mediated antitumor activity. Recent efforts have capitalized on the anti-N-acetyllactosamine action of fluorinated glucosamines to treat antitumor T cells, resulting in diminished Gal-1-binding and higher antitumor T cell levels. In this perspective, the prospect of fluorinated glucosamines in eliminating N-acetyllactosamines on antitumor T cells to boost antitumor immunity is presented.

Copyright © 2012 Elsevier Ltd. All rights reserved.

PMID:
23219268
[PubMed - indexed for MEDLINE]
PMCID:
PMC3604137
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1
Figure 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk